Inosine: A Bioactive Metabolite with Multimodal Actions in Human Diseases

Overview

Journal Front Pharmacol

Date 2022 Dec 5

PMID 36467085

Authors

In Soo Kim

Eun-Kyoung Jo

Affiliations

Soon will be listed here.

Abstract

The nucleoside inosine is an essential metabolite for purine biosynthesis and degradation; it also acts as a bioactive molecule that regulates RNA editing, metabolic enzyme activity, and signaling pathways. As a result, inosine is emerging as a highly versatile bioactive compound and second messenger of signal transduction in cells with diverse functional abilities in different pathological states. Gut microbiota remodeling is closely associated with human disease pathogenesis and responses to dietary and medical supplementation. Recent studies have revealed a critical link between inosine and gut microbiota impacting anti-tumor, anti-inflammatory, and antimicrobial responses in a context-dependent manner. In this review, we summarize the latest progress in our understanding of the mechanistic function of inosine, to unravel its immunomodulatory actions in pathological settings such as cancer, infection, inflammation, and cardiovascular and neurological diseases. We also highlight the role of gut microbiota in connection with inosine metabolism in different pathophysiological conditions. A more thorough understanding of the mechanistic roles of inosine and how it regulates disease pathologies will pave the way for future development of therapeutic and preventive modalities for various human diseases.

Citing Articles

Investigating intestinal epithelium metabolic dysfunction in celiac disease using personalized genome-scale models.

McCreery C, Alessi D, Mollo K, Fasano A, Zomorrodi A BMC Med. 2025; 23(1):95.

PMID: 39984962 PMC: 11846356. DOI: 10.1186/s12916-025-03854-0.

The effect of intraoperative inosine infusion on transplant outcomes in deceased-donor kidney transplant recipients.

Luo Y, Zhang Y, Tang Z, Zhang J, Na N, Xiao H Ren Fail. 2024; 46(2):2436629.

PMID: 39627170 PMC: 11616739. DOI: 10.1080/0886022X.2024.2436629.

Identification of Spatial Specific Lipid Metabolic Signatures in Long-Standing Diabetic Kidney Disease.

Zhang Y, Piao H, Chen D Metabolites. 2024; 14(11).

PMID: 39590877 PMC: 11596753. DOI: 10.3390/metabo14110641.

Investigating the relationship between blood metabolites and diabetic retinopathy using two-sample mendelian randomization and in vivo validation.

Zeng Y, Mo G, Wang X, Yang Y, Dong Y, Zhong R Sci Rep. 2024; 14(1):22947.

PMID: 39362968 PMC: 11450153. DOI: 10.1038/s41598-024-73337-4.

Study of gut microbiome alterations in plaque psoriasis patients compared to healthy individuals.

Polak K, Muszynski T, Fratczak A, Meznerics F, Banvolgyi A, Kiss N Postepy Dermatol Alergol. 2024; 41(4):378-387.

PMID: 39290901 PMC: 11404103. DOI: 10.5114/ada.2024.142394.

References

Fredholm B, IJzerman A, Jacobson K, Klotz K, Linden J . International Union of Pharmacology. XXV. Nomenclature and classification of adenosine receptors. Pharmacol Rev. 2001; 53(4):527-52. PMC: 9389454. View

Matsuo H, Tomiyama H, Satake W, Chiba T, Onoue H, Kawamura Y . ABCG2 variant has opposing effects on onset ages of Parkinson's disease and gout. Ann Clin Transl Neurol. 2015; 2(3):302-6. PMC: 4369280. DOI: 10.1002/acn3.167. View

Sliva J, Pantzartzi C, Votava M . Inosine Pranobex: A Key Player in the Game Against a Wide Range of Viral Infections and Non-Infectious Diseases. Adv Ther. 2019; 36(8):1878-1905. PMC: 6822865. DOI: 10.1007/s12325-019-00995-6. View

Nakahama T, Kawahara Y . Adenosine-to-inosine RNA editing in the immune system: friend or foe?. Cell Mol Life Sci. 2020; 77(15):2931-2948. PMC: 11104962. DOI: 10.1007/s00018-020-03466-2. View

Raghava Kurup R, Oakes E, Manning A, Mukherjee P, Vadlamani P, Hundley H . RNA binding by ADAR3 inhibits adenosine-to-inosine editing and promotes expression of immune response protein MAVS. J Biol Chem. 2022; 298(9):102267. PMC: 9418441. DOI: 10.1016/j.jbc.2022.102267. View

Guinzberg R, Cortes D, Diaz-Cruz A, Riveros-Rosas H, Villalobos-Molina R, Pina E . Inosine released after hypoxia activates hepatic glucose liberation through A3 adenosine receptors. Am J Physiol Endocrinol Metab. 2005; 290(5):E940-51. DOI: 10.1152/ajpendo.00173.2005. View

Kutryb-Zajac B, Mierzejewska P, Slominska E, Smolenski R . Therapeutic Perspectives of Adenosine Deaminase Inhibition in Cardiovascular Diseases. Molecules. 2020; 25(20). PMC: 7587364. DOI: 10.3390/molecules25204652. View

Lima G, de Oliveira Lopes R, Mendes A, Brazao S, Autran L, Motta N . Inosine, an endogenous purine nucleoside, avoids early stages of atherosclerosis development associated to eNOS activation and p38 MAPK/NF-kB inhibition in rats. Eur J Pharmacol. 2020; 882:173289. DOI: 10.1016/j.ejphar.2020.173289. View

El-Shamarka M, El-Sahar A, Saad M, Assaf N, Sayed R . Inosine attenuates 3-nitropropionic acid-induced Huntington's disease-like symptoms in rats via the activation of the A2AR/BDNF/TrKB/ERK/CREB signaling pathway. Life Sci. 2022; 300:120569. DOI: 10.1016/j.lfs.2022.120569. View

10.

Li Q, Gloudemans M, Geisinger J, Fan B, Aguet F, Sun T . RNA editing underlies genetic risk of common inflammatory diseases. Nature. 2022; 608(7923):569-577. PMC: 9790998. DOI: 10.1038/s41586-022-05052-x. View

11.

Brown E, Arellano-Santoyo H, Temple E, Costliow Z, Pichaud M, Hall A . Gut microbiome ADP-ribosyltransferases are widespread phage-encoded fitness factors. Cell Host Microbe. 2021; 29(9):1351-1365.e11. PMC: 8429246. DOI: 10.1016/j.chom.2021.07.011. View

12.

de Reuver R, Verdonck S, Dierick E, Nemegeer J, Hessmann E, Ahmad S . ADAR1 prevents autoinflammation by suppressing spontaneous ZBP1 activation. Nature. 2022; 607(7920):784-789. DOI: 10.1038/s41586-022-04974-w. View

13.

Mabley J, Pacher P, Liaudet L, Soriano F, Hasko G, Marton A . Inosine reduces inflammation and improves survival in a murine model of colitis. Am J Physiol Gastrointest Liver Physiol. 2002; 284(1):G138-44. DOI: 10.1152/ajpgi.00060.2002. View

14.

Teixeira F, de Mattos B, de Mello J, Cardoso J, Spohr L, Luduvico K . Protective Effects of Inosine on Memory Consolidation in a Rat Model of Scopolamine-Induced Cognitive Impairment: Involvement of Cholinergic Signaling, Redox Status, and Ion Pump Activities. Neurochem Res. 2021; 47(2):446-460. DOI: 10.1007/s11064-021-03460-5. View

15.

Liu Y, Hoang T, Taylor C, Park E, Freeborn J, Luo M . and differentially affect gut microbes and metabolites in mice with Treg deficiency. Am J Physiol Gastrointest Liver Physiol. 2021; 320(6):G969-G981. PMC: 8285589. DOI: 10.1152/ajpgi.00072.2021. View

16.

Jain M, Jantsch M, Licht K . The Editor's I on Disease Development. Trends Genet. 2019; 35(12):903-913. DOI: 10.1016/j.tig.2019.09.004. View

17.

Pfaller C, George C, Samuel C . Adenosine Deaminases Acting on RNA (ADARs) and Viral Infections. Annu Rev Virol. 2021; 8(1):239-264. DOI: 10.1146/annurev-virology-091919-065320. View

18.

Teixeira F, Gutierres J, Soares M, da Siveira de Mattos B, Spohr L, do Couto C . Inosine protects against impairment of memory induced by experimental model of Alzheimer disease: a nucleoside with multitarget brain actions. Psychopharmacology (Berl). 2019; 237(3):811-823. DOI: 10.1007/s00213-019-05419-5. View

19.

Garcia-Gil M, Camici M, Allegrini S, Pesi R, Tozzi M . Metabolic Aspects of Adenosine Functions in the Brain. Front Pharmacol. 2021; 12:672182. PMC: 8160517. DOI: 10.3389/fphar.2021.672182. View

20.

Rice G, Kasher P, Forte G, Mannion N, Greenwood S, Szynkiewicz M . Mutations in ADAR1 cause Aicardi-Goutières syndrome associated with a type I interferon signature. Nat Genet. 2012; 44(11):1243-8. PMC: 4154508. DOI: 10.1038/ng.2414. View